Edwards Lifesciences also presented TRISCEND II six-month data for first 150 patients successfully demonstrating safety, efficacy of the EVOQUE system
Edwards EVOQUE transcatheter tricuspid valve replacement SYSTEM Receives CE markEdwards Lifesciences also presented TRISCEND II six-month data for first 150 patients successfully demonstrating safety, efficacy of the EVOQUE system with improvements in quality-of-life and functional outcomes for patientsNEWBURY,...
Edwards Lifesciences Phil Maccarthy Nick Walker King College Hospital Prof Phil Maccarthy Interventional Consultant Cardiologist
Source: pharmiweb.com